Dawn Bell

Chief Executive Officer
Antlia Bioscience

Dawn Bell, Pharm.D. is a biopharma executive, former start-up CEO and Board Director with experience at large and mid-sized public pharmaceutical companies, as well as early stage and start-up privately held biotech companies. Her areas of expertise span strategic planning, portfolio prioritisation, clinical development, business development, market access and commercialisation. Dr. Bell is currently CEO of Antlia Bioscience, a pre-clinical stage company developing long-acting biologics for patients with serious cardiovascular diseases. Former to joining Antlia Biosciences, she was Global Development Head of Strategic Partnerships at Novartis where she is responsible for portfolio strategy for internal and external white space opportunities. She is also a board member and member of the audit and finance committee for The Metabolomics Innovation Center in Edmonton, Alberta, a nationally-funded research facility. She is a passionate mentor for seed stage life-sciences start-ups in the Creative Destruction Lab (Toronto, Canada) as well as EIT Health’s Gold Track Programme.